BioHybrid Solutions LLC (BHS) is a Carnegie Mellon University spin-off, focused on next generation protein-polymer biotherapeutics as alternatives to PEGylation. We are a fast-growing company with a network of committed partners and collaborators working to deliver the next generation of biotherapeutics.